Cypros Pharmaceutical Corp. appoints Robert F. Allnutt to its board of directors.CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 14, 1996--Cypros Pharmaceutical Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CYPR) announced today the appointment of Robert F. Allnutt to join its Board of Directors. Allnutt's recent posts include executive vice president of the Pharmaceutical Manufacturer's Association from 1985-1995 where he supervised issues such as health policy formulation, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. reform, drug pricing and managed care. Allnutt has also held senior management positions at Comsat and NASA NASA: see National Aeronautics and Space Administration. NASA in full National Aeronautics and Space Administration Independent U.S. where he held the third ranking position. He holds a B.S. degree in engineering from Virginia Polytechnic Institute and J.D. and L.L.M. degrees from George Washington University George Washington University, at Washington, D.C.; coeducational; chartered 1821 as Columbian College (one of the first nonsectarian colleges), opened 1822, became a university in 1873, renamed 1904. . He is a member of the Board of Directors of the National Health Council and the National Council on Aging. Paul J. Marangos, Ph.D., chief executive officer of Cypros commented, "We are pleased and fortunate to have Mr. Allnutt join our Board. He brings an extensive and broad pharmaceutical industry perspective in the health policy, regulatory and government arenas, as well as hands-on operational experience. He is highly respected by the entire pharmaceutical community and will serve Cypros well in this next phase of our growth as we transition to an operating company." Cypros Pharmaceutical develops cytoprotective drugs and markets acute-care, hospital-based products. The company has two clinical development programs and several drugs in pre-clinical research. Six Phase II trials are currently in progress, which include four for CPC-111 (acute complications of angioplasty, coronary artery bypass grafting surgery, congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. and sickle cell anemia sickle cell anemia n. A chronic, usually fatal inherited form of anemia marked by crescent-shaped red blood cells, occurring almost exclusively in Blacks, and characterized by fever, leg ulcers, jaundice, and episodic pain in the joints. crises), and two for CPC-211 (stroke and head injury). The company also markets two intravenous agents (Inulin inulin /in·u·lin/ (in´ul-in) a starch occurring in the rhizome of certain plants, yielding fructose on hydrolysis, and used in tests of renal function. in·u·lin n. and Glofil) used to assess kidney function and one injectable drug (Ethamolin) for the treatment of esophageal varices. CONTACT: David W. Nassif Vice President and Chief Financial Officer 619/929-9500 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion